Doctors are hesitant to treat myeloma patients with kidney involvement with lenalidomide (REVLIMID) or other drugs that could be potentially harmful to kidney production. Learn with us if REVLIMID can be used successfully in patients with kidney involvement and come with your questions.
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
From a young age, I was interested in science. As a biology major, I became fascinated with the ways cells divide and become cancerous. Through a series of translational research experiences, I witnessed how basic science findings could be brought to the bedside and improve people’s health. My interest in cancer biology and passion for patient care, research, and teaching prompted me to pursue a combined MD/PhD degree program and subsequent certification in hematology and oncology. Every patient that comes to me has a unique story and individual experience. I enjoy getting to know each person and providing personalized care and treatment options that suit his or her needs. At Perlmutter Cancer Center, I treat people with various types of malignant and benign hematologic conditions, with an emphasis on hematologic cancers. I have a specialty focus on plasma cell disorders, particularly multiple myeloma. I also see patients who have iron deficiency, bleeding and clotting disorders, and cancers involving the bone marrow and lymph nodes, such as lymphomas. Our comprehensive care team at NYU Langone Hospital—Long Island is highly trained to deliver innovative treatment options, conduct clinical trials, and offer supportive care to patients with blood disorders. I routinely perform bone marrow biopsies and therapeutic phlebotomy for certain conditions. Also, I co-direct the Autologous Stem Cell Transplantation Program, managing patients’ care throughout the transplant process. I encourage my patients to participate in clinical trials, which have the potential to improve outcomes. In addition, I collaborate with laboratory scientists to better understand the pathogenesis of multiple myeloma.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113